According to the new prices notified by the drug price regulator, the ceiling price of Glucose Injection 5% 1000ml NonGlass with special features is Rs.95.10, Glucose Injection 5% 500ml Non-Glass with special features is Rs.82.27, Glucose plus Sodium Chloride Injection 5% plus 0.9% 1000ml Non-Glass with special features is Rs.99.93, Glucose plus Sodium Chloride Injection 5% plus 0.9% 500ml Non-Glass with special features is Rs. 85.51, Sodium Chloride Injection 0.9%100ml Non-Glass with special features is Rs.42.05, Sodium Chloride Injection 0.9%250ml Non-Glass with special features is Rs.62.10, Sodium Chloride Injection 0.9% 500ml Non-Glass with special features is Rs.87.93 and Sodium Chloride Injection 0.9% 1000ml Non-Glass with special features is Rs.98.49.
The notice declared that in exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O.1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016, S.O.5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 1500(E) dated 30.03.2022 andS.O.4591(E) dated 29.09.2022in so far as they relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, has revised the price based on Wholesale price index(WPI) of 2022 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:
(a) The ceiling prices are applicable with effect from 01.04.2023 (ceiling prices are inclusive of Wholesale Price Index (WPI) @12.1218% for the year 2022 over 2021).
(b) In the case of M/s Puniska Healthcare Pvt. Ltd. mentioned in Sl. No. 19 of Table B, only the prices of the formulations specified in Sl. No. 5, 6, 7 & 8 of Table A are applicable.
(c) In the case of M/s Higgs Healthcare mentioned in Sl. No. 21 of Table B, only the prices of the formulations specified in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable.
(d) In the case of M/s Puerto Life Sciences Private Limited mentioned in Sl. No. 23 of Table B, only the prices of the formulations specified in Sl. No. 2, 4 & 7 of Table A are applicable.
(e) In the case of M/s Sachin Parenteral Pvt. Ltd. mentioned in Sl. No. 24 of Table B, only the prices of the formulations specified in Sl. No. 2, 4, 5, 6 & 7 of Table A are applicable.
(f) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(g) The manufacturers of the above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 1500(E) dated 30.03.2022 and S.O. No. 4591(E) dated 29.09.2022(plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 12.1218% for the year 2022 over 2021 in accordance with paragraph 16(2) of DPCO, 2013.
(h) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.
(i) Any other manufacturer claiming a separate ceiling price for Non-Glass with a special feature shall apply to NPPA for separate ceiling price approval with details and demonstrate, that such pack along with documentation and demonstration.
(j) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision, and non-submission of the information under this subparagraph shall be construed as a non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), along with interest thereon from the date of overcharging.
(k) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
